Every 10-Q that Elite Pharmaceuticals Inc (ELTP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ELTP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELTP filings page.
Elite Pharmaceuticals, Inc. reported for the quarter ended June 30, 2026 revenue of $32.4 million, down from $40.2 million a year earlier, as increased competition, including on its Lisdexamfetamine line, reduced average net pricing. Cost of manufacturing rose to $18.8 million, cutting gross margin to 42% from 68% and reducing income from operations to $7.5 million from $21.7 million.
Despite weaker operating results, the company posted net income of $5.9 million, compared with a $5.9 million loss in the prior-year quarter, helped by a much smaller impact from warrant fair-value adjustments and higher interest income. Operating cash flow was strong at $10.1 million, and cash and restricted cash increased to $39.4 million. The balance sheet shows total assets of $139.7 million, liabilities of $34.8 million, and shareholders’ equity of $104.8 million, with working capital of $84.0 million.
Elite continues to expand its generic portfolio, launching methadone tablets in April 2026 and a generic Requip XL (ropinirole extended-release) in July 2026, and it filed an anticoagulant ANDA and reported positive pivotal bioequivalence results for an anticonvulsant generic. A patent suit by Purdue Pharma relating to Elite’s generic OxyContin ANDA was dismissed by court order in June 2026. Revenue remains concentrated, with two customers representing 73% of sales.
Elite Pharmaceuticals reported sharply improved results for the quarter and nine months ended December 31, 2025. Total revenue reached $31.6 million this quarter and $108.1 million year‑to‑date, up from $14.4 million and $52.0 million a year earlier, driven mainly by higher manufacturing fees.
Net income was $18.6 million for the quarter versus a $10.9 million loss last year, and $26.4 million year‑to‑date versus a $21.3 million loss. Results include a sizeable non‑cash gain from changes in warrant fair value. Basic EPS was $0.02 for both the quarter and nine months.
Cash and restricted cash increased to $21.6 million from $8.7 million year‑earlier, helped by $14.6 million of operating cash flow and repayment of $4.0 million and $1.0 million of related‑party loans. One customer represented 64% of revenue and 70% of receivables, and the company continues ANDA‑focused operations while pursuing new generic launches and managing ongoing patent litigation over a proposed generic OxyContin.
Elite Pharmaceuticals (ELTP) reported a strong Q2 FY2026. Total revenue reached $36,321,704 for the quarter, up from $18,880,345 a year ago, driven by manufacturing fees. Gross profit was $14,073,033. Income from operations rose to $8,213,746. A $7,519,649 favorable change in warrant fair value lifted other income, resulting in net income attributable to common shareholders of $13,702,407, or $0.01 per basic and diluted share.
For the six months, revenue was $76,532,801 with income from operations of $29,913,453 and net income of $7,817,692 after $7,308,441 of income tax expense. Cash was $26,617,346 as of September 30, 2025, up from $11,315,385, aided by $19,880,115 net cash from operating activities; related party loans of $4,000,000 were repaid. Accounts receivable rose to $40,871,924, and warrant liabilities were $39,789,081. Shares outstanding were 1,074,496,422 as of November 14, 2025. Subsequent to quarter end, the FDA approved Elite’s ANDA for generic Requip XL (Ropinirole ER tablets) under the Elite Laboratories label.